Figure - PMC

Skip to main content

An official website of the United States government

Here's how you know

Here's how you know

Official websites use .gov
A .gov website belongs to an official government organization in the United States.

Secure .gov websites use HTTPS
A lock ( ) or https:// means you've safely connected to the .gov website. Share sensitive information only on official, secure websites.

View full-text article in PMC

. 2018 Jan 23;9(13):11145–11158. doi: 10.18632/oncotarget.24298

Search in PMC
Search in PubMed
View in NLM Catalog
Add to search

Copyright: © 2018 Macek Jilkova et al.

This is an open-access article distributed under the terms of the Creative Commons Attribution License 3.0 (CC BY 3.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.

PMC Copyright notice

(A) MTT assay on Hep3B cell line after 48h of treatments showing significant decrease in cell viability with increasing concentrations of combination treatment of ARQ 092 and sorafenib (constant ratio IC₅₀: IC₅₀). Combination index (CI = 0.053) at effective dose 50 (ED₅₀) revealed strong synergy. (B) Additive effects of combination treatment of ARQ 092 and sorafenib on apoptosis in Hep3B after 48h of exposure. P values in graph represent ANOVA comparison of ARQ 092 IC₅₀, sorafenib IC₅₀ and Combination IC₅₀/10. P value of ANOVA test of all groups is indicated in the corner of the graph (p <0.0001). (C) The quantification of migration (decrease of width of the wound after 24h) in Hep3B. Additive effects of combination treatment of ARQ 092 and sorafenib. P values in graph represent ANOVA comparison of ARQ 092 IC₅₀, sorafenib IC₅₀ and Combination I IC₅₀/10. P value of ANOVA test of all groups is indicated in the corner of the graph (p =0.0001). Control was set as 100%, values are means ± SE from three independent experiments performed in triplicates (A) and in duplicates (B, C).